CTIS2024-511446-39-00Active, not recruitingPhase 1
An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB) - EIP22-NFD-505
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Eip Pharma Inc.
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •Men and women aged =55 years., Subject is willing and able to provide written informed consent., Probable DLB by consensus criteria (McKeith et al, 2017; McKeith et al, 2020)., MoCA score =18 during Screening., If the patient is currently receiving cholinesterase inhibitor and/or memantine therapy, the patient must have received such therapy for greater than 3 months and on a stable dose for at least 6 weeks at the time of randomization. Except for reducing the dose for tolerability reasons, the dose of cholinesterase inhibitor may not be modified during the study. If the patient is not currently receiving such therapy, but received such therapy previously, that therapy must have been discontinued at least 3 months prior to randomization., Normal or corrected eyesight and auditory abilities, sufficient to perform all aspects of the cognitive and functional assessments., No history of learning difficulties that may interfere with their ability to complete the cognitive tests., Received vaccination for SARS-CoV-19 unless medical contraindications prevent being vaccinated or has a history of natural infection., Must have reliable informant or caregiver.
Exclusion Criteria
- •Diagnosis of any other ongoing central nervous system (CNS) condition other than DLB, including, but not limited to, post-stroke dementia, vascular dementia, Alzheimer’s disease (AD), Frontotemporal dementia (FTD), or Parkinson’s disease (PD)., If male with female partner(s) of child-bearing potential, unwilling or unable to adhere to contraception requirements specified in the protocol., If female who has not has not reached menopause >1 year previously or has not had a hysterectomy or bilateral oophorectomy/salpingo-oophorectomy, has a positive pregnancy test result during Screening and/or is unwilling or unable to adhere to the contraception requirements specified in the protocol., Ongoing major and active psychiatric disorder and/or other concurrent medical condition that, in the opinion of the Investigator, might compromise safety and/or compliance with study requirements., Diagnosis of alcohol or drug abuse within the previous 2 years., Poorly controlled clinically significant medical illness, such as hypertension (blood pressure >180 mmHg systolic or 100 mmHg diastolic); myocardial infarction within 6 months; uncompensated congestive heart failure or other significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would interfere with assessment of drug safety., Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 × the upper limit of normal (ULN), total bilirubin >1.5 × ULN, and/or International Normalized Ratio (INR) >1.5. If patient is taking blood thinners (e.g., warfarin), and has no known liver issues, INR >3., Known tuberculosis, human immunodeficiency virus, hepatitis B, or active hepatitis C virus infection., Participated in a study of an investigational drug less than 6 weeks or 5 half-lives of an investigational drug, whichever is longer, before enrollment in this study., Receipt of a live vaccine, with the exception of influenza, within 4 weeks before starting study drug treatment., History of previous neurosurgery to the brain within the past five years.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)CTIS2023-504373-20-00Eip Pharma Inc.160
Active, not recruiting
Not Applicable
Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients attending a Specialist Clinic - Phase II Open-Label Pilot Study of V3381 in Chronic CoughMedDRA version: 9.1Level: LLTClassification code 10066656Term: Chronic coughTreatment resistant and Idiopathic Chronic CoughEUCTR2009-011525-13-GBVernalis (R&D) Limited20
Completed
Phase 2
ONO-4538 Phase 2 study (ONO-4538-88/TASUKI-88)Malignancies (Gastric Cancer/Non-Small Cell Lung Cancer)JPRN-jRCT2080225262ONO PHARMACEUTICAL CO., LTD.60
Completed
Phase 2
ONO-4538 Phase II Study (ONO-4538-91/TASUKI-91)Patients with unresectable or recurrent biliary tract cancer (including intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, and duodenal papilla cancer) that is refractory or intolerant to gemcitabine-based and S-1-based regimens with CPS >=1.JPRN-jRCT2080225006ONO PHARMACEUTICAL CO., LTD.80
Active, not recruiting
Phase 1
A clinical study to investigate the efficacy and safety of copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma.EUCTR2014-004848-36-ITBayer HealthCare AG67